Financials data is unavailable for this security.
View more
Year on year FibroGen Inc grew revenues 4.99% from 140.73m to 147.75m. Additionally the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as percentages of sales). These changes narrowed profitability losses from -293.65m to -284.23m.
| Gross margin | 76.87% |
|---|---|
| Net profit margin | -69.48% |
| Operating margin | -62.75% |
| Return on assets | -34.51% |
|---|---|
| Return on equity | -- |
| Return on investment | -103.81% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at FibroGen Inc fell by 42.01m. However, Cash Flow from Investing totalled 153.66m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 315.02m for operations while cash generated from financing totalled 122.75m.
| Cash flow per share | -1.22 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | -2.42 |
|---|---|
| Tangible book value per share | -2.42 |
More ▼
Balance sheet in USDView more
| Current ratio | 1.28 |
|---|---|
| Quick ratio | 1.16 |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | -- |
More ▼
